ALK inhibitors in the treatment of patients with NSCLC
MUDr. Libor Havel
Pneumologická klinika 1. LF UK a Thomayerovy nemocnice, Praha
Patients with EML4-ALK translocation represent small, but clinically interesting subgroup of patients with non-small cell lung cancer. Since this genetic alteration revealing we are witness of rapid progress in therapy of these patients. ALK (anaplastic lymphoma kinase) inhibitors became a standard therapy in first line treatment, second generation ALK inhibitors are available in clinical practice and higher lines are tested. This article would be a summarisation of recent attitude to ALK inhibitors in NSCLC.
non-small cell lung cancer, crizotinib, ceritinib, alectinib, brigatinib, lorlatinib, entrectinib, resistance
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...